TABLE 3.

Clinical summary for eight patients whose fungemia was recurrent even after CVC removal

Patient no.	Age/sexa	Admission cause	Fungemia episode	Fungemia durationb	CVC removal (day[s]b)	Antifungal drug, dose/day (therapy durationb)
10	25 days/M	Staphylococcus aureus sepsis	First	0–3	Yes (3)	None
			Recurrent	7–12	No	Amphotericin, 0.5 mg/kg (9–18)
11	62 yr/M	Myasthenia gravis	First	0–7	Yes (5)	Fluconazole, 200 mg (7–17)
			Recurrent	50–85	Yes (85)	Fluconazole, 200 mg (86–100)
12	52 yr/M	Bronchial asthma	First	0–35	Yes (3, 35)	Amphotericin, 0.5 mg/kg (11–35)
			Recurrent	48–67	Yes (67)	Amphotericin, 0.5 mg/kg (66–78)
13	40 yr/F	Tuberculous meningitis	First	0–7	Yes (8)	Amphotericin, 0.5 mg/kg (4–25)
			Recurrent	13–27,c 38	Yes (28)	Amphotericin, 0.5 mg/kg (41–47)
14	43 yr/M	Acute renal failure	First	0–18	Yes (18)	Amphoterin, 0.5 mg/kg (18–30)
			Recurrent	156–160	Yes (160)	Amphotericin, 0.5 mg/kg (160–174)
15	22 yr/M	Acute renal failure	First	0	Yes (3)	None; fluconazole, 200 mg (7–24)d
			Recurrent	19–27c	Yes (27)	Amphotericin, 0.5 mg/kg (25–34)
16	76 yr/M	Intracranial hemorrhage	First	0–3	Yes (3)	Fluconazole, 400 mg (0–19)
			Recurrent	23	No	None
17	62 yr/M	Traffic accident	First	0–2	Yes (2)	Amphotericin, 0.5 mg/kg (4–11)
			Recurrent	11c	Yes (11)	Amphotericin, 0.5 mg/kg (11–26)

^aM, male; F, female. 

^bNumber of days after the first positive blood culture in each patient. 

^cFungemia occurred during antifungal therapy in three patients. 

^dPatient 15 underwent antifungal therapy for the treatment of C. albicans candidemia.